Designed to be fast, accurate, and accessible, Molbio’s innovations allow timely testing and treatment to support improved health outcomes for people, everywhere.
From concept to large-scale deployment, our technologies showcase our drive to advance equitable access to advanced healthcare for all.
At Molbio, innovation drives our mission. From proof of concept to real-life settings, our innovation are adaptable and future ready to health crises- from infectious to neglected tropical diseases. Our relentless pursuit of excellence, combined with cutting-edge technology solutions, bridges gaps in infrastructure, enabling healthcare professionals to practice precise medicine.
With 40+ million lives touched across 85+ countries, Molbio has successfully decentralized healthcare access by bringing the gold-standard molecular diagnostics test out of the centralized laboratory systems to the last mile. This empowers communities to fight healthcare inequities, ensuring health for all. At the end of the day, why should the benefits of science be limited to just a few?
We understand the importance of a level playing field to enable groundbreaking innovation to come to life. Molbio's EDGE, a global accelerator programme that is designed to bridge the critical gaps between innovation and market adoption for point-of-need diagnostic technologies by integrating experience, expertise, and state-of-the-art facilities.
At Molbio, innovation drives our mission. By creating portable, real-time diagnostic solutions, we challenge traditional healthcare models, making advanced technology accessible to everyone. Our relentless pursuit of excellence bridges gaps in infrastructure, enabling precision healthcare anywhere, anytime, and redefining the boundaries of what’s possible in global diagnostics.
Our solutions are more than technology—they’re life-changing tools. With 40+ million lives touched across 80+ countries, Molbio empowers communities with early detection and timely treatment. By decentralizing diagnostics, we combat healthcare inequities, ensuring even the remotest regions benefit from transformative solutions that improve outcomes and save lives.
Molbio inspires a new era of healthcare by proving innovation and accessibility can coexist. We’re not just creating products; we’re igniting movements, fostering collaboration, and motivating global action. Our journey fuels hope, proving that the future of healthcare is brighter when driven by purpose, passion, and pioneering technology.
Five years ago, the Indian diagnostics industry was still quite modest. However, with innovators like Molbio leading the way, things have begun to change. During the pandemic, one of the most remarkable shifts in India was the rapid increase in both the volume of diagnostic tests and their affordability.
India has developed indigenous technologies like AI-based digital X-rays and molecular diagnostics tools such as the Truenat for programmatic management, disease surveillance, and treatment monitoring - a testament to our commitment to Make in India.
Molbio's Truenat stands out among point-of-care innovations for TB testing. This compact, battery-operated PCR device detects multiple pathogens, making it ideal for primary health centers. It identifies TB, influenza, dengue, malaria, and hepatitis. We hope governments will scale it up, moving away from unreliable smear microscopy.
The inclusion of India's Truenat molecular assay by WHO's Global TB Programme as the initial test for TB and MDR-TB, due to its high accuracy, is a proud moment for the Indian Council of Medical Research (ICMR) and the Department of Health Research (DHR). This marks the culmination of a long journey in promoting indigenous TB diagnostics developed by Indian scientists.
With 91% domestic funding and indigenous technology like Truenat, India has successfully established a diagnostic network of 8293+ NAAT systems in the country and has moved away from reliance on Cephied's GeneXpert monopoly.
The roll-out of Truenat under the STOP TB Partnership’s ‘introduction of New Tools Project’ (iNTP) in Bantayan Island, Philippines, has significantly boosted the detection of presumptive TB instances.
As a portable real-time PCR, Truenat has effectively addressed the logistical challenges associated with a centralised lab system, making the same-day ‘Test and Treat’ initiative a reality in Uganda.
In line with the 'Make in India' initiative, we have launched our indigenous Truenat machines for TB detection and drug susceptibility testing.
We are proud to have recently launched 451 Truenat machines across Uttar Pradesh, providing widespread access to the gold standard RT-PCR test. The presence of a Truenat machine in every district and hospital was instrumental in our successful response to COVID-19, significantly enhancing our testing capabilities and ensuring timely diagnostics.
Connect with us
Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
© All Rights Reserved
